文献速递慢性静脉疾病

GLP-1受体激动剂使用与静脉性溃疡愈合及伤口感染减少相关

GLP-1 Receptor Agonist Use Is Associated with Venous Ulcer Healing and Fewer Wound Infections.
PubMed 文献 · Ann Vasc Surg · 2026-03-25

基于TriNetX网络101家医疗机构的381512例静脉性溃疡患者数据,经1:1倾向匹配后纳入38834对,比较启用与未启用GLP-1受体激动剂者的结局。1年随访时,GLP-1受体激动剂组不愈合溃疡比例更低(0.61% vs 0.92%,P<0.01),伤口相关感染住院更少(18.4% vs 30.8%,P<0.01),主要不良心血管事件和主要不良肢体事件均减少。

要点

  • GLP-1受体激动剂与静脉性溃疡不愈合风险降低相关(0.61% vs 0.92%,P<0.01)
  • GLP-1受体激动剂与伤口相关感染住院减少相关(18.4% vs 30.8%,P<0.01)
  • GLP-1受体激动剂组主要不良心血管事件和主要不良肢体事件均减少

核心结论

  • GLP-1受体激动剂使用与静脉性溃疡愈合改善相关。
  • 使用GLP-1受体激动剂的静脉性溃疡患者因伤口相关并发症住院及发生主要不良心血管事件的可能性更低。

研究设计与样本

  • 数据来源于TriNetX研究网络,涵盖101家医疗机构。
  • 采用1:1倾向匹配研究,比较活动性静脉性溃疡患者中启用GLP-1受体激动剂组与未启用组。
  • 匹配控制年龄、种族、性别、糖尿病状态、吸烟史和基线体重。
  • 排除踝肱指数异常定义的动脉功能不全患者。
  • 2022年10月1日至2023年12月31日共识别381512例静脉性溃疡患者,匹配后研究人群为38834对。

主要发现

  • GLP-1受体激动剂组起始平均体重更高(247 ± 68.2 vs. 216 ± 64.2,P = 0.001)。
  • GLP-1受体激动剂组血红蛋白A1c更高(7.7 ± 0.8 vs. 7.2 ± 0.8,P < 0.01)。
  • 1年随访时,GLP-1受体激动剂组体重下降更明显(240 ± 65.0 vs. 212 ± 63.5,P < 0.01)。
  • 1年随访时,GLP-1受体激动剂组不愈合溃疡更少(0.61% vs. 0.92%,P < 0.01)。
  • 1年随访时,GLP-1受体激动剂组伤口相关感染住院更少(18.4% vs. 30.8%,P < 0.01)。

关键数值与推荐

  • 多因素分析发现GLP-1受体激动剂与伤口持续存在、软组织感染、住院、主要不良心血管事件和主要不良肢体事件风险降低显著相关。

临床怎么用

  • 对合并糖尿病或肥胖的静脉性溃疡患者,GLP-1受体激动剂可能有助于改善溃疡愈合并减少伤口相关感染住院。
  • 启用GLP-1受体激动剂时需关注其与主要不良心血管事件和主要不良肢体事件减少的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic venous leg ulcers are a prevalent and debilitating complication of chronic venous insufficiency. Up to 20% of patients with venous ulcers are diabetic, and up to 50% struggle with obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an established class of agents used primarily for the treatment of type 2 diabetes and obesity. Studies have repeatedly demonstrated that their use is associated with reductions in major adverse cardiac events (MACEs) and major adverse limb events (MALEs), but their effects on venous ulcer healing have not yet been investigated. METHODS: Data were sourced from the TriNetX Research Network, encompassing 101 health care organizations. We utilized a 1:1 propensity-matched study to compare patients with an active venous ulcer and started on GLP-1 RAs (group 1) with those who were not started on GLP-1 RAs (group 2). To control for differences in the cohorts, we controlled for age, race, sex, diabetes status, smoking history, and baseline weight. Outcomes included wound healing, inpatient admission, MACE, and MALE, which were identified using International Classification of Diseases, Tenth Revision codes. Patients with arterial insufficiency defined by an abnormal ankle-brachial index were excluded. RESULTS: We identified 381,512 patients with venous ulcers between October 1, 2022, and December 31, 2023. After propensity matching, we arrived at a study population of 38,834 matched pairs. Patients in group 1 were found to have a higher starting mean weight (247 ± 68.2 vs. 216 ± 64.2, P = 0.001) and hemoglobin A1c (7.7 ± 0.8 vs. 7.2 ± 0.8, P < 0.01). At the 1-year follow-up period, group 1 exhibited more weight loss (240 ± 65.0 vs. 212 ± 63.5, P < 0.01), fewer nonhealing ulcers (0.61% vs. 0.92%, P < 0.01), and fewer inpatient admissions for wound-related infection (18.4% vs. 30.8%, P < 0.01). Both MACEs and MALEs were decreased in group 1. Multivariate analysis found GLP-1 RAs to be significantly associated with decreased risk of persistence of wounds, soft tissue infections, inpatient admissions, MACEs, and MALEs. CONCLUSION: The use of GLP-1 RAs is associated with improved venous ulcer healing. Patients with venous ulcers treated with GLP-1 RAs are also less likely to be admitted to the hospital with wound-associated complications and suffer MACEs.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Go CC, Annie F, Drabish K, et al. GLP-1 Receptor Agonist Use Is Associated with Venous Ulcer Healing and Fewer Wound Infections. Ann Vasc Surg. 2026. PMID: 41895589. doi:10.1016/j.avsg.2026.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。